INS and type 1 diabetes mellitus: Because islets and especially β-cells are sensitive to commonly used immunosuppressive drugs (123, 124), there is an even more pronounced need for refined immunosuppressive strategies in β-cell replacement therapies, which can restore metabolic control more efficiently than exogeneous insulin therapy and prevent the serious long-term complications and co-morbidities associated with T1D (125–128).